Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 4/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397349 | 1.00 | BTK (0.41) | BTKMAPK1CDK7MAPK8MAPK14 | |
| SCHEMBL21397411 | 0.84 | MAPK1 (0.37) | MAPK1MAPK8MAPK14MAPK9MAPK10 | |
| SCHEMBL21397323 | 0.82 | BTK (0.43) | BTKMAPK1CDK7MAPK8MAPK9 | |
| SCHEMBL16665607 | 0.82 | BTK (0.43) | BTKMAPK1CDK7MAPK8MAPK9 | |
| SCHEMBL16665663 | 0.79 | BTK (0.47) | BTKMAPK1CDK7MAPK8MAPK9 | |
| SCHEMBL18074058 | 0.79 | BTK (0.47) | BTKMAPK1CDK7MAPK8MAPK9 | |
| SCHEMBL21397410 | 0.78 | CDK7 (0.45) | CDK7CDK9 | |
| SCHEMBL16665651 | 0.78 | CDK7 (0.45) | CDK7CDK9 | |
| SCHEMBL22759954 | 0.78 | MAPK1 (0.40) | BTKMAPK1CDK7MAPK8MERTK | |
| SCHEMBL21265827 | 0.78 | MAPK1 (0.40) | BTKMAPK1CDK7MAPK8MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015058163-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | BTK 3238/4885MAPK1 521/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.